News

Mar 20

LAM to Present Data for Cell-Free DNA Methylation Assay for Non-Invasive Diagnosis of Liver, Breast and Colorectal Cancers at AACR Annual Meeting 2019

Data Showcase the High Diagnostic Potential of LAM’s Circulating Cell-Free DNA Methylation Assay for the Early Detection of Multiple Cancers

IRVINE, Calif., Mar. 20, 2019 — Laboratory for Advanced Medicine (LAM), a commercial-stage medical technology company focused on developing innovative technologies for the early diagnosis of cancers, announced today a poster presentation titled “Circulating Cell-Free DNA Methylation Assay: Towards Early Detection of Multiple Cancer Types” will be presented at the American Association for Cancer Research (AACR) Annual Meeting on March 31 from 1:00 p.m. – 5:00 p.m. EDT at the Georgia World Congress Center in Atlanta, Georgia. The poster presentation will include new data that further validates the high diagnostic potential of LAM’s cell-free DNA methylation assay to non-invasively diagnose liver, breast and colorectal cancers with high specificity and sensitivity.
Presentation Information:
Title: “Circulating Cell-Free DNA Methylation Assay: Towards Early Detection of Multiple Cancer Types”
Authors: Dhruvajyoti Roy, David Taggart, Lianghong Zheng, Dan Liu, Gen Li, Mingzhen Li, Kang Zhang, Richard A. Van Etten
Session Date: Sunday, March 31
Session Time: 1:00 p.m. – 5:00 p.m. EDT
Poster Session location: Section 36
Meeting abstracts are available at AACR’s website.
About Laboratory for Advanced Medicine
LAM is a commercial-stage medical technology company focused on developing innovative, noninvasive, nontoxic technologies for the early diagnosis and intervention of cancers. The company is dedicated to building and growing world-class technologies from the laboratory to the clinic.
Headquartered in the United States with offices in California, Texas and Indiana, LAM has collaborations with leading scientists, physicians, research institutions and business leaders in the U.S. and China, combining their experiences to provide the most effective and safest diagnostic technologies to patients and their doctors. The company has CLIA-registered and CAP-accredited as well as third-party laboratories and cGMP facilities all working toward bringing first-class technologies to the medical community today.
Media Contacts:
Ignacio Guerrero-Ros, PhD
Russo Partners
Tel: (646) 942-5604
ignacio.guerrero-ros@russopartnersllc.com
Alex Fudukidis
Russo Partners
Tel: (646) 942-5632
alex.fudukidis@russopartnersllc.com